DISEASE CATEGORY: Cardiovascular INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury. The...

CHMP backs Ebola vaccine, targeted cancer therapies EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor met the primary endpoint of reducing major adverse cardiovascular events (MACE) in the Phase III THEMIS trial in patients with coronary artery disease and Type II diabetes with...

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...

Idorsia Ltd. (SIX:IDIA) said single subcutaneous injections of selatogrel (ACT-246475) inhibited platelet aggregation within 15 minutes with its maximum effect extending over 4-8 hours depending on the dose in a pair of Phase II trials...

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) said PB2452 (formerly MEDI2452) rapidly and completely reversed the antiplatelet activity of cardiovascular drug Brilinta ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) in a Phase I trial. The company is developing...